Gt Biopharma, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
GT Biopharma, a clinical-stage biopharmaceutical company, reported a significant net loss and substantial doubt about its ability to continue as a going concern, despite advancing its TriKE product pipeline.
NASDAQ
GT Biopharma files an amendment to its 2024 Form 10-K to include the company's Compensation Recovery Policy as an exhibit.
NASDAQ
10-K: GT Biopharma Reports Full Year 2024 Results, Highlights Clinical Progress and Financial Position
GT Biopharma's 2024 10-K filing reveals ongoing clinical development of its TriKE platform, challenges in maintaining Nasdaq listing compliance, and a net loss of $13.2 million.
NASDAQ
GT Biopharma's 2023 annual report highlights a year of clinical development progress and financial adjustments, including a reverse stock split and a focus on next-generation TriKE therapies.